Currently Viewing:
American Society of Hematology
Dr Derek Raghavan Explains How Use of Guidelines Can Address Issues of Cost and Variation
May 26, 2018
Dr Derek Raghavan: Evidence-Based Guidelines Will Improve Cancer Outcomes, Reduce Costs
May 09, 2018
Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education
May 01, 2018
Dr Derek Raghavan Provides Best Practices for Implementing Guidelines
April 26, 2018
Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care
April 18, 2018
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17, 2018
Dr Derek Raghavan Addresses the Concept of "Cookbook Medicine"
April 09, 2018
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 07, 2018
Dr Thomas LeBlanc: How to Increase Palliative Care Among Patients With Blood Cancer
April 02, 2018
Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer
March 21, 2018
Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care
March 10, 2018
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14, 2018
Dr Julie Wolfson on What Clinicians Need to Understand About Adolescents/Young Adults With ALL
December 30, 2017
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29, 2017
Currently Reading
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017

Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies

Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.


Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.

Transcript

What education efforts are needed for patients and clinicians when new treatments like CAR T therapies first emerge?

It’s an institutional commitment if one is going to do CAR T-cell therapy; it’s not just a single physician or physician’s office. It involves multiple people, there’s a chain of people that are involved from the blood bank or transfusion service that receives the cells and thaws the cells and administers the cells to the physicians and nurse practitioners and nurses that are caring for the patients during infusion and after infusion of the cells.

And those people need to be educated not only in the specific adverse events of special interest—cytokine release, neurotoxicity—but also in terms of handling the cells and making sure that the patient is in the proper environment for surveillance for subsequent syndromes, either as an outpatient or an inpatient, depending on the product used. Most leukemia patients, kids, will be admitted to the hospital.

So, what’s helpful is the sponsors of the 2 products that have a commercial label, that’s tisagenlecleucel or Kymriah, and the other one is axicabtagene ciloleucel, which is called Yescarta, they have REMS [Risk Evaluation and Mitigation Strategy] programs. So, these are programs that will educate people at all points in the chain on what to expect, what the roles are, what the proper responses are and actually have a test and things like that. And that’s the first step in getting educated.

Obviously, experience is important and the only way you can get that is by doing it. I think that people who are new to it, in addition to the REMS programs, should probably have a relationship with someone who is experienced, so if they run into problems they have somebody they can call and bounce problems off of.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!